Vivoryon Therapeutics N.V. (LON:0R3M)
London
· Delayed Price · Currency is GBP · Price in EUR 1.798
+0.004 (0.22%)
At close: Apr 28, 2025
Vivoryon Therapeutics Statistics
Total Valuation
LON:0R3M has a market cap or net worth of GBP 39.26 million. The enterprise value is 31.32 million.
| Market Cap | 39.26M |
| Enterprise Value | 31.32M |
Important Dates
The last earnings date was Thursday, April 24, 2025.
| Earnings Date | Apr 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.14% |
| Shares Change (QoQ) | +6.30% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 21.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 6.02 |
| P/TBV Ratio | 6.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.84 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.98 |
Financial Position
The company has a current ratio of 7.20, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.20 |
| Quick Ratio | 6.74 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -243.77 |
Financial Efficiency
Return on equity (ROE) is -120.41% and return on invested capital (ROIC) is -76.39%.
| Return on Equity (ROE) | -120.41% |
| Return on Assets (ROA) | -62.23% |
| Return on Invested Capital (ROIC) | -76.39% |
| Return on Capital Employed (ROCE) | -212.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.13M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +124.75% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +124.75% |
| 50-Day Moving Average | 1.89 |
| 200-Day Moving Average | 2.08 |
| Relative Strength Index (RSI) | 45.39 |
| Average Volume (20 Days) | 250 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.34M |
| Pretax Income | -17.01M |
| Net Income | -17.01M |
| EBITDA | -17.22M |
| EBIT | -17.34M |
| Earnings Per Share (EPS) | -0.65 |
Balance Sheet
The company has 7.80 million in cash and 84,351 in debt, giving a net cash position of 7.71 million.
| Cash & Cash Equivalents | 7.80M |
| Total Debt | 84,351 |
| Net Cash | 7.71M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.52M |
| Book Value Per Share | 0.25 |
| Working Capital | 7.17M |
Cash Flow
In the last 12 months, operating cash flow was -15.86 million and capital expenditures -1,654, giving a free cash flow of -15.86 million.
| Operating Cash Flow | -15.86M |
| Capital Expenditures | -1,654 |
| Free Cash Flow | -15.86M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LON:0R3M does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.14% |
| Shareholder Yield | -3.14% |
| Earnings Yield | -43.32% |
| FCF Yield | -40.39% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |